Advancing drug discovery and treatment evaluation for schistosomiasis : improved screening, drug repurposing and rescuing, and the metabonomics of praziquantel treatment by Panić, Gordana
 
 
 
 
Advancing drug discovery and treatment evaluation 
for schistosomiasis: improved screening, drug 
repurposing and rescuing, and the metabonomics of 
praziquantel treatment 
 
 
Inaguraldissertation 
 
Zur  
Erlangung der Würde eines Doktors der Philosophie vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
von 
Gordana Panic 
aus Kanada  
Basel, 2018 
 
 
 
 
Original document stored on the publication server of the University of Basel 
edoc.unibas.ch 
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 
International License. 
 
 
 
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf 
Antrag von: 
 
Prof. Dr. Jürg Utzinger, Prof. Dr. Jennifer Keiser, und Dr. Piero Olliaro 
 
Basel, den 21 Februar 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Prof. Dr. Martin Spiess 
        Dekan 
 
 
1 
 
Table of Contents 
 
Acknowledgments ................................................................................................................ 2 
Summary ............................................................................................................................... 4 
Table of Abbreviations ......................................................................................................... 7 
Chapter 1- Introduction ........................................................................................................ 8 
Chapter 2- Investigations of novel automated in vitro screening assays  ..................... 40 
Chapter 2a - Fluorescence/luminescence-based markers for the assessment of 
Schistosoma mansoni schistosomula drug assays. ....................................................... 41 
Chapter 2b - A novel isothermal microcalorimetry tool to assess drug effects on 
Ancylostoma ceylanicum and Necator americanus........................................................ 54 
Chapter 3- Drug repurposing for schistosomiasis ........................................................... 65 
Chapter 3a - Repurposing drugs for the treatment and control of helminth infections.. .. 66 
Chapter 3b - Activity profile of an FDA-approved compound library against Schistosoma 
mansoni... ..................................................................................................................... 83 
Chapter 4- Rescuing old antischistosomals  .................................................................... 99 
Chapter 4a - Aryl hydantoin Ro 13-3978, a broad-spectrum antischistosomal.. ........... 100 
Chapter 4b - Immunohistochemical investigations of treatment with Ro 13-3978, 
praziquantel, oxamniquine and mefloquine in Schistosoma mansoni-infected mice.. .. 111 
Chapter 4c – Ferrocenyl, ruthenocenyl, and benzyl oxamniquine derivatives with cross-
species activity against Schistosoma mansoni and Schistosoma haematobium .......... 126 
Chapter 5- Dynamics of schistosomiasis infection and praziquantel treatment in pre-
school and school-aged children  ................................................................................... 135 
Chapter 5a - Efficacy and safety of praziquantel in preschool-aged and school-aged 
children infected with Schistosoma mansoni: a randomized controlled, parallel-group, 
dose-rangin, phase 2 trial.. .......................................................................................... 136 
Chapter 5b - Characterizing the biochemical response to Schistosoma mansoni infection 
and treatment with praziquantel in preschool and school-aged children.. .................... 147 
Chapter 6- Discussion  ..................................................................................................... 154 
 
  
 
 
2 
 
Acknowledgements 
 
This thesis was a highly collaborative effort with excellent scientists and colleagues 
and would not have been as enjoyable without the support of family and friends. 
Therefore, I have many people to thank. 
First and foremost, I am immensely grateful to my thesis supervisor, Prof. Jennifer 
Keiser, for the opportunity to engage in this wonderful scientific escapade. I’ve had 
the privilege of supervision from someone with an open door, ears and mind that 
nonetheless provides fresh input, motivation and firm feedback and guidance. I look 
hopefully look forward to more great exchanges in the future.  
I am indebted to my referee and examining committee. Thank you to Dr. Piero Olliaro 
for taking the time in his busy schedule to join as an external co-referee on my 
committee. Moreover, thank you to Dr. Jon Swann for agreeing to examine me on the 
metabonomics portion of the thesis. Finally, a special thanks to Dr. Jurg Utzinger for 
his flexibility on joining on as Faculty Representative.  
My collaborations have been a constant source of joy, innovation and cohesive 
teamwork with excellent scientists and genuinely great people. First, I owe my 
deepest gratitude to Dr. Jean Coulibaly from Côte d’Ivoire. Without his tremendous 
efforts, the clinical trial on which the metabonomics work rests would not have been 
possible. His stamina, organizational prowess and care for his work and community 
are a source of inspiration.  
The metabonomics studies would not have been possible without the will of Dr. 
Elaine Holmes and particularly the tutelage and hosting of Dr. Jonathan Swann. I am 
very grateful to have been able to learn from their expertise and engage in this work. 
Thank you also to Nikita Harvey for her NMR expertise and assistance. 
I recognize Dr. Christer Wallin and Dr. Magnus Jansson, for organizing for us to test 
the calScreener™ independently and for the technical support. I am very grateful to 
Dr. Olivier Braissant for providing his encyclopedic calorimetric expertise and for the 
great discussions.  Finally, I was fortunate to have Dayana Flores as my Master 
student, who came at the projects with enthusiasm, persistence, great ideas and wit.  
 
 
3 
 
The serendipitous collaboration on the EIS microfluidics platform has grown to a full 
new project. I am truly appreciative to Dr. Sebastian Bürgel for the innovative 
exchanges, mutual motivation and fun. Thank you Dr. Andreas Hierlemann, head of 
the Bio Engineering Laboratory, for taking on the project. I am truly excited and 
grateful to the new team, Flavio , Mario and Ketki, who are already doing a fantastic 
job.  
I am grateful to Dr. Jonathan Vennerstrom and Dr. Paul Davies for the easy-going but 
stimulating exchanges on the Ro 13-3978 studies. I am particularly indebted to Dr. 
Theresa Ruf for her incredible competence (histological and otherwise), open door 
and general warmth.  
I am also fortunate to have benefited from the ongoing fruitful collaborations of our 
unit with Prof. Dr. Gilles Gasser. My appreciation extends to Dr. Jeannine Hess for 
her great ideas for the organometallic compounds and the excellent and collegial 
discussions.  
The ups and downs of this work have been shared with some truly amazing and 
supportive colleagues. To all my former colleagues, Beni, Urs, Katrin, Isabel, 
Lucienne and Noemi, you set great precedents for both scientific work and teamwork. 
To my current colleagues, Beatrice, Jana, Valerio, Flavio, Wendelin, Marta, Anna, 
Pierre, Eveline and now Marlene, it’s always fun to come to the office because of 
you, and even more fun to toast after work. Moreover, we are all indebted to Mireille 
Vargas as our trusted lab technician and so very much more. A big thank you to all 
my coffee and dance floor partners in crime from the broader Swiss TPH family.  
Throughout all this time, I’ve had endless encouragement from friends and family. I 
am particularly grateful to my long-time flatmates, for the mutual support and 
sisterhood. I was especially touched by the constant warmth, hospitability and 
support of the Urech family. I also want to thank all my friends back home and abroad 
for the long-distance support and endless friendship after all this space and time.  
To my partner, Christian Urech, thank you to listening to all my talking and then 
turning it all into a laugh. Finally, I have infinite gratitude to my family: from my 
Popovic, Novkovic and Lolin clan in the east, to my Panic clan – my parents Aleksej 
and Zelimirka and my sister Aleksandra -in the west. If I didn’t already have a reason, 
you would be it.   
Summary 
 
4 
 
Summary 
 
Schistosomiasis is a widespread chronic inflammatory disease caused by a parasitic 
blood fluke of the Schistosoma genus, primarily by S. mansoni, S. haematobium and 
S. japonicum. More than 200 million people in low-resource rural dwellings of the 
tropics and sub-tropics are affected, 90% of which are in Africa and many of which 
are children. The chronic disease is characterized by anemia, abdominal pain, bloody 
stool or urine, portal hypertension, swelling and degradation of the liver, spleen, 
intestines or the urogenital organs, caused by hypersensitivity reactions to eggs that 
become lodged in visceral organs.  
The main strategy for control endorsed by the World Health Organization is morbidity 
reduction by mass administration of the only drug available, praziquantel. The 
treatment is safe and effective but carries important drawbacks such as its lack of 
efficacy against juvenile worm stages and its child-unfriendly bitter taste. Importantly, 
the reliance on a single drug to treat millions is unwise and treatment alternatives are 
required. Yet schistosomiasis falls into the category of neglected tropical diseases, so 
called because their treatment and drug candidate arsenal is marginal compared to 
their public health impact.  
This PhD thesis had two major aims. The first was to mitigate this need for novel 
antischistosomal drug candidates by exploring automated in vitro drug screening 
systems and by invoking drug repurposing, rescuing and re-designing strategies to fill 
the pipeline. The second was to enhance our understanding of schistosomiasis and 
its treatment with praziquantel in pre-school and school-aged children with a clinical 
dose-finding trial and complementary metabonomic investigations.  
In testing 11 fluorescence/luminescence-based viability/cytotoxicity markers, 
resazurin, Vybrant® and CellTiter-Glo® presented as markers that correlated with S. 
mansoni larval stage viability. Of these, CellTiter-Glo® could determine IC50 values 
for some standard drugs in the range of microscopically assessed values and was 
100% accurate in identifying hits from a small sub-set of a screen.  
An evaluation of a new calorimetry device, the calScreener™, showed that heat flow 
and heat flow fluctuation signals from single adult stage worms of two nematodes 
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could be used to monitor worm viability over time. However, this did not extend to S. 
mansoni adult stage nor larval stage worms. 
A literature review of drug repurposing anthelmintic in vivo and clinical trial 
candidates detailed the continued reliance on veterinary drug discovery as a source 
for new compounds, largely for nematodes. Antimalarials were found to be an 
important contributor of antischistosomal drug candidates, though additional sources, 
such as anticancer drugs are increasingly in the foreground.  
To expand repurposing sources, we screened an open-source library of 1600 FDA 
approved compounds against S. mansoni in vitro and in vivo.  Our screen identified 
121 hits against Newly Transformed Schistosomula (NTS, the larval stage) at a 
concentration of 10 µM and 36 active compounds on the adult stage at a 
concentration of 33 µM. Despite needing to discard many compounds for 
pharmacokinetic or toxicity reasons, 11 compounds were tested further in vivo, with 
doramectin (10 mg/kg) and clofazimine (400 mg/kg) showing significant worm burden 
reductions of 60.1% and 82.7%, respectively. 
In seeking to revive a pre-praziquantel era antischistosomal candidate, Ro 13-3978 
was characterized for its activity against S. mansoni. In vitro, it displayed only minor 
activity against adult S. mansoni. In vivo it was more potent than praziquantel with an 
ED50 of 14.6 and 138.9 mg/kg against adult and juvenile stage worms respectively. 
Hepatic shift and SEM studies of ex-vivo worms showed minimal activity within the 
first 24 h but by 48 h were worms are shunted to the liver and the tegument 
thoroughly damaged. Further investigations with immunohistochemistry on 
histological sections of treated versus non-treated mice indicated significant 
recruitment of macrophages and B cells to the worm at 24 h post-treatment and 
additional recruitment of T cells and neutrophils at 48 h post treatment.  
Oxamniquine was re-designed by synthesizing organometallic derivatives. Three 
compounds- a ferrocenyl, a ruthenocenyl and a benzyl derivative- presented potent 
in vitro activity against adult S. mansoni worms, reducing their viability by > 75% 
within 4 to 7 h after exposure. This contrasted with oxamniquine, which presents no 
activity in vitro. In S. mansoni-infected mice, a 100 mg/kg dose of the derivatives 
reduced worm burden by 76 to 93%, comparable to the worm burden reduction of 
oxamniquine at the same dose. 
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Our randomized controlled dose-finding clinical trial of praziquantel in school-aged 
and pre-school aged children infected with S. mansoni in southern Côte d’Ivoire 
showed slightly lower efficacy of praziquantel in pre-school versus school-aged 
children. When administered either a placebo or 20, 40, 60 mg/kg praziquantel, cure 
rates for pre-schoolers were 37.1, 62.2, 72.2 and 71.4%, respectively, as compared 
to those for school-aged children which were 11.9, 30.4, 68.8 and 82.9%, 
respectively. An Emax model predicted an egg reduction rate of 99% with 65 mg/kg 
praziquantel for school-aged children while for pre-schoolers, this was not in range.  
Metabonomic analyses of urine samples from this same clinical trial revealed that 
heavily infected children could be differentiated from non-infected children prior to 
treatment, indicating potential urinary biomarkers of morbidity. Treatment with 
praziquantel produced a plethora of metabolic responses 24h after treatment, which 
differed between pre-school and school aged children, which may be linked to the 
diferring treatment success rates between the two groups. Most metabolites were 
correlated to energy, liver and gut microbial metabolisms.  
In conclusion, we present CellTiter Glo® as a possible hit/no hit pre-screening tool for 
in vitro assays. Moreover, our FDA library screen proposes additional sources of drug 
indications from which antischistosomal compounds and scaffolds could be sourced. 
Meanwhile Ro 13-3978 is an efficacious antischistosomal, active against multiple 
stages of infection, and presents as an excellent pre-clinical candidate worthy of 
further investigations. The oxamniquine derivatives described elucidate a successful 
drug re-design strategy using organometallic derivatization. Finally, praziquantel 
treatment itself has been better characterized for an increasingly important 
demographic population, pre-school aged children, and illustrated through a systemic 
metabolic lens. 
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1.1 Epidemiology and global disease burden of schistosomiasis 
 
Schistosomiasis is a disease of tremendous global public health concern. It is widely 
distributed throughout the tropics and sub-tropics and found mostly in poor rural 
areas, (Adenowo et al., 2015; WHO, 2016a). The causative agents are parasitic 
flatworms of the genus Schistosoma: S. mansoni, S. haematobium and S. japonicum 
are the main culprits, whereas S. mekongi, S. intercalatum and S. guineensis are 
less often implicated (Gryseels, 2012). There are two main forms of the disease. 
Intestinal schistosomiasis is caused mainly by S. mansoni and S. japonicum, 
whereas the urinary form is caused only by S. haematobium, which nonetheless 
accounts for 64% of infections (Hotez et al., 2006). 
Throughout 78 countries, around 779 million people live at risk of infection, 85% of 
which are living in Africa (Steinmann et al., 2006a). With over 200 million people 
infected, resulting in 2.6 million DALYs lost, schistosomiasis is third only to malaria in 
terms of global disease burden associated with a parasitic disease (Kassebaum et 
al., 2016).  
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Figure 1 Global distribution of schistosomiasis according to species and 
prevalence. (Adapted from Colley et al., 2014 and WHO, 2012). 
Schistosomiasis is a water-borne disease whereby transmission occurs by exposure 
to contaminated freshwater (Gryseels et al., 2006). Distribution is centered around 
significant and minor fresh water bodies and can often be focal. Consequently, 
development and management of water resources, such as dams and irrigation 
systems, are a significant risk factor for schistosomiasis (Steinmann et al., 2006a). 
Moreover, those most exposed to contaminated waters, such as rice farmers, 
fisherman or mothers and children that bathe and wash in rivers, are most at risk, 
though some acquisition of immunity is apparent in adulthood (Colley and Secor, 
2014; Ismail et al., 2014; Steinmann et al., 2006b). Importantly, provision of safe 
water and human waste disposal infrastructure as well as safe hygienic practices are 
protective against this disease (Grimes et al., 2015).  
 
1.2 Biology and lifecycle 
Schistosoma worms are digenetic trematodes- parasitic flatworms with two sexes, a 
syncytial tegument and a ventral and oral sucker (Olson et al., 2003). The adult 
worms are about 1-2 cm long, complete with a blind digestive tract, reproductive 
organs and a primitive neuromuscular system. Sexual diphormism is very evident: 
the female is long and thin with a tegumental texture akin to an elephant trunk 
whereas the male is wide with a tegument patterned by distinct tubercules (Hockley, 
1973; Humans, 2012). The female resides in the gynocephoral canal of the male and 
they remain in a monogamous state of copulation for years inside the host, where 
they produce tens to thousands of eggs per day (Cheever et al., 1994).   
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Figure 2 (A) Life cycle of Schistosoma spp. (B) Adult worm morphology. (C) 
Species-specific eggs and their (D) intermediate snail hosts. (Adapted from: 
CDC, 2012; Gouvras, 2014; Gray et al., 2011; Lewis et al., 2008; Wikimedia 
Commons, 2015) 
 
Humans become infected when they come into contact with freshwater bodies 
infested with cercariae, the free-swimming infectious stage of Schistosoma spp. The 
cercariae burrow through the host skin by using the propulsive force of their flagella, 
in combination with secreting serine proteases from acetabular glands that digest 
skin proteins (Ligasová et al., 2011; Salter et al., 2000). Penetration takes anywhere 
from 2-24 hours and in the process, the tail breaks off (McKerrow and Salter, 2002). 
The remaining schistosomula locate blood vessels and circulate in the blood until 
they reach the lungs, where they reside in the pulmonary capillaries and enter the 
juvenile stage. At around 4 to 6 weeks post-infection, the worms migrate to the liver 
where they will sexually mature to their adult form, mate, and relocate to the veins of 
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the mesenteries, or in the case of urogenital schistosomiasis, vesicular veins of the 
bladder or urogenital organs (Gryseels, 2012). There they reside for an average of 2 
to 5 years, employing a multitude of immune evasion mechanism to protect from the 
hostile humoral environment (Gryseels et al., 2006; Pearce and MacDonald, 2002). 
The tens to thousands of eggs they shed trigger Th2-type immune responses, which 
the eggs co-opt in order to assist their migration through the intestinal or bladder 
walls (Pearce, 2005). They are thus expelled with the feces (intestinal 
schistosomiasis) or urine (urogenital schistosomiasis). When eggs come into contact 
with fresh water, they hatch into aquatic free-swimming forms called miracidia, which 
locate their intermediate species-specific snail host via chemotactic and chemokinetic 
mechanisms (Macinnis et al., 1974). In the snails, they undergo multiple rounds of 
asexual reproduction through mother and daughter sporocyst stages. In a matter of 
four to six weeks, the snails start to shed cercariae, the infective form of the parasite 
(Doughty, 1996). Cercariae are viable for one to three days and in this time, they 
actively pursue their definite host also using phototaxis and chemotaxis (McKerrow 
and Salter, 2002).  
 
1.3 Pathology 
Within hours of penetration through the skin by the cercariae, a rash characterized by 
maculopapular lesions, known as “swimmer’s itch” may appear. In temperate zones, 
this can also be caused by avian cercariae wrongly attacking the wrong host, but 
does not lead to infection (Bourée and Caumes, 2004).  
Schistosomiasis follows an acute, then a chronic phase. The acute phase, called 
Katayama syndrome, presents as general flu-like symptoms: fever, myalgia, fatigue, 
nausea, pain in the abdomen, coughing, eosinophilia and urticaria are but a few 
(Jesus et al., 2002; Ross et al., 2007). Symptoms are thought to be the result of 
hypersensitivity reactions to the migrating schistosomula (Ross et al., 2002). Notably, 
in endemic populations, both swimmer’s itch and the acute phase are often absent, 
though both heavy re-infections and re-infection with S. japonicum can elicit strong 
acute reactions (Ross et al., 2002; Zhou et al., 2005). Because it can come several 
weeks to several months after infection, and because of its unspecific presentation, it 
is the phase most likely to be misdiagnosed by travel physicians (Ross et al., 2007).  
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Most of the morbidity associated with schistosomiasis is attributable to the chronic 
phase of the disease which is in turn attributable to eggs produced by the adult 
worms (Murray et al., 2012). If left untreated, the adult worms continue to shed eggs 
daily, only half of which are expelled by the feces or urine. The other half are either 
swept by circulating blood or are unsuccessful in their migration and consequently 
become lodged in proximal organs  (Colley et al., 2014). These eggs elicit strong 
Th2-type immune responses,  encapsulating the eggs into granulomas and 
eventually resulting in fibrosis and sometimes necrosis of the tissue (Fairfax et al., 
2012). Overtime, this leads to chronic inflammation, swelling and deterioration of 
affected organs. The severity of the pathology is thus highly correlated with infection 
intensity, but variation in host genetics and immune responses may play a role 
(Colley et al., 2014; Pearce and MacDonald, 2002; Russell et al., 2015). 
In gastrointestinal schistosomiasis, the inflamed intestinal wall may be plagued by 
hyperplasia, abscesses and polyp formation, which cause alternating constipation 
and diarrhea, bloody stools and gastric pain. Overtime, severe infection may lead to 
colonic or rectal stenosis (Gray et al., 2011). Inflammation, hardening granulatomous 
lesions and calcified collagen deposits result in hepatomegaly and liver cirrhosis. 
Obstruction of blood flow, portal hypertension and anemia follow (Barsoum et al., 
2013). Portal hypertension itself can provoke dilation of sub-mucosal veins in the 
esophagus, leading to lethal ascites and hematemesis (Richter et al., 1998).  
In the case of urinary schistosomiasis, the lesions in the bladder cause hematuria 
and dysuria, apparent early at two to three months post-infection (King and Bertsch, 
2013). Overtime, calcifications and polyps in the bladder wall lead to downstream 
consequences such as obstructive uropathy (usually concomitant with bacterial 
superinfection and renal dysfunction) or squamous-cell carcinoma of the bladder 
(Gray et al., 2011).  Female genital schistosomiasis is due to eggs trapped in various 
organs of the genital tract, which can also lead to cancers and has strong and often 
neglected consequences for female reproductive health (Kjetland et al., 2012).   
Neuroschistosomiasis is a rare but severe disease caused by ectopic migration of 
eggs or worms to areas of the central nervous system (Carod-Artal, 2008). Meningitis 
and epilepsy as well as other central nervous system disorders manifest and are 
mostly associated with S. japonicum infection (Ross et al., 2012).  
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Over the long term, schistosomiasis is associated with malnutrition, particularly iron 
deficiency, growth stunting and cognitive inhibition (King, 2007). Due to its slow but 
debilitating long term effects, it is one of the diseases that is said to perpetuate the 
poverty trap (Hotez et al., 2009).  
1.4 Diagnosis 
Clinical diagnosis of schistosomiasis relies on a combination of medical history and 
sign and symptom evaluation and confirmation with laboratory tests. The current gold 
standard for detecting Schistosoma infections is by microscopic examination of 
stools, for intestinal schistosomiasis, or urine, for urinary schistosomiasis, for 
presence of species-specific eggs (Gray et al., 2011). In hospital settings, the direct 
thick smear along with the formalin ether concentration method are often used 
(Utzinger et al., 2010).  Epidemiological surveys require more quantitative methods. 
For urinary schistosomiasis, a simple urine syringe filtration and microscopic 
evaluation of the filter permits a quantification of eggs per 10 ml urine. For intestinal 
schistosomiasis, the most widely employed method is the Kato-Katz thick smear, 
differentiated from the direct smear by a platform that allows for easy mounting of a 
specific amount of stool and thus the quantification of eggs per gram feces (Katz et 
al., 1972). Notably, concomitant helminth infections can also be detected in this 
manner. However, both the filtration and Kato-Katz methods are vulnerable to day-to- 
day egg output variation and are insensitive to low intensity infections.  Multiple 
sampling and read-outs are therefore recommended (Booth et al., 2003; Ebrahim et 
al., 1997; Knopp et al., 2013, p. 2013; Lamberton et al., 2014).  The FLOTAC and its 
subsequent, field-friendly Mini-FLOTAC employ egg-flotation methods and allow for 
sampling of a larger quantity of stool sample. They appear to have a superior 
sensitivity over the above-mentioned methods, with a detection limit of 10 eggs per 
gram (EPG) (Barda et al., 2013; Glinz et al., 2010).  
For the accurate mapping and impact monitoring of control programs, sensitive point-
of-care (POC) dipstick diagnostics are desired (Utzinger et al., 2015). 
Microhematuria- detecting reagent strips for the detection of S. haematobium (King 
and Bertsch, 2013) and the POC-CCA (circulating cathodic antigen) for the detection 
of S. mansoni, S. japonicum and S. mekongi infections (Stothard et al., 2006; van 
Lieshout et al., 2000) have shown superior sensitivity over the above-described 
microscopic methods (Coulibaly et al., 2011; Danso-Appiah et al., 2016; van Dam et 
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al., 2015b, 2015a). A new generation of monoclonal antibody based “up-converting 
phosphor-lateral flow” (UCP-LF) CAA tests can even detect single-worm S. mansoni 
infections (Corstjens et al., 2008), are able to detect S. japonicum infections with 10-
fold higher sensitivity than microscopic methods (van Dam et al., 2015b) and were 
found to be more sensitive than urine filtration for the detection of S. haematobium.  
Serological tests for the detection of circulating antibodies against Schistosoma 
antigens include several different enzyme-linked immunosorbent assays (ELISAs), 
indirect hemagglutination assays (IHAs), and immunofluorescent-antibody tests 
(IFATs) which can detect either adult worm antigens (AWA), soluble egg antigens 
(SEA) or cercarial antigens (CA) (Kinkel et al., 2012). These tests are generally not 
suitable for use in endemic populations, as they are not able to discriminate between 
active infection versus previous exposure. They can be useful as clinical tools for 
testing potentially infected travelers. However, the degree of sensitivity and specificity 
can greatly vary from test to test and as a result, using at least two tests is 
recommended (Doenhoff et al., 2004).  
Finally, the vast array of molecular techniques, such as PCR, for the detection of 
parasite DNA are generally the most specific and sensitive but are far less suitable in 
endemic countries due to the costly equipment and specialized staff required (Verweij 
and Stensvold, 2014). However, the exciting developments in loop-mediated 
isothermal amplification (LAMP) technology could render these techniques 
accessible to resource-constrained areas (Utzinger et al., 2015). 
1.5 Control strategies and treatment 
Despite many interesting pre-clinical and clinical developments, a vaccine for 
schistosomiasis will likely not be within reach soon (Tebeje et al., 2016). An optimal 
control strategy would include vector control (e.g. molluscicide spraying), health 
education, hygiene and sanitation measures (e.g. Water Sanitation and Hygiene  
(WASH)) and anthelmintic treatment (Inobaya et al., 2014). However, as the former 
can be difficult to sustainably implement and measure, the mainstay of the WHO 
control strategy is regular preventative chemotherapy for morbidity reduction (Hotez 
et al., 2007).  
Praziquantel, introduced in the 1970s by Bayer, is the drug of choice used in 
preventative chemotherapy programs. It is a broad anthelmintic, active against all 
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species of Schistosoma infecting humans as well as many cestodes. It has been a 
very important drug as its safety, efficacy and ease of use (single oral dose: 40 
mg/kg) has made it possible to treat millions of people worldwide. Nonetheless, it 
carries drawbacks. First it is a racemic tablet, where the S- praziquantel enantiomer 
is fairly inactive (Meister et al., 2014). Second, it is not effective against the juvenile 
stage, meaning developing infections are not treated during mass drug administration 
campaigns (Pica-Mattoccia and Cioli, 2004, p.; Wu et al., 2011). Finally, it is literally a 
very bitter pill to swallow, which can make it difficult to administer effective doses to 
young children.  
There are several studies hinting at the mode of action of praziquantel but no definite 
smoking gun (Wu et al., 2011). Though it is known that praziquantel disrupts Ca2+ 
homeostasis in adult worms, the actual molecular target has remained elusive 
(Angelucci et al., 2007; Greenberg, 2005). Evidence points to praziquantel binding to 
beta sub-units of voltage-gated Ca2+channels as the target (Kohn et al., 2003; Pica-
Mattoccia et al., 2007). However, direct interaction of praziquantel with channel 
subunits has never been observed (Angelucci et al., 2007). Moreover, additional 
targets have also been explored such as glutathione s-transferase, adenosine 
receptors and surface-membrane actin (Angelucci et al., 2007; McTigue et al., 1995; 
Tallima and El Ridi, 2007). 
Oxamniquine was introduced around the same time as praziquantel, but in contrast, it 
is only active against S. mansoni, and no other helminths. For a long time, it was 
used as the mainstay of schistosomiasis control in Brazil. However, its use was 
halted in the 1990s as resistance to the drug could already be demonstrated in the 
early 1970s (Coura and Amaral, 2004; Webster et al., 2014). Since then, the drug 
has been obsolete. However, it’s mechanism of action, unlike that of praziquantel, is 
very well characterized (Valentim et al., 2013). Oxamniquine is a prodrug that binds 
to an endogenous S. mansoni-specific sulfotransferase. In conjugation with 
3’phosphoadenosine 5’phosphosulfate (PAPS), it is sulfonated to an unstable 
intermediate which degrades into an electrophilic molecule that alkylates proximate 
DNA, proteins and other macromolecules (Pica-Mattoccia et al., 2006). 
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 Figure 3 (A) Praziquantel (PZQ) and its enantiomers. (B) Oxamniquine (OXA) 
prodrug and active form.  
1.6 Need for new treatments  
In 2014, more than 258 million people were estimated to be in need of treatment, 
about half of which were children and 91% of which were living in the African region 
(WHO, 2016b). However, only 21% of these received preventative chemotherapy and 
only 58% of endemic countries reported on coverage (WHO, 2016b). In 2012, the 
World Health Assembly adopted resolution WHA65.1, which called for increased 
investment in schistosomiasis control and support for countries to eliminate the 
disease (WHO, 2012). Along with clean water and hygiene interventions, vector 
control and health education, treatment is targeted to expand to 235 million people by 
2018. Increased treatment coverage is required to reach this ambitious goal but 
raises concerns of drug resistance in the face of increased selective pressure. It is 
therefore imminent that treatment alternatives be developed.  
Challenges to anthelmintic drug development are abundant.  A hallmark of NTDs is 
that they are generally poorly funded even despite their significant public health 
impact and need for new and better drugs. In fact, according to a 2015 G-FINDER 
report, less than 1% of global R&D funding was spent on schistosomiasis, where only 
$ 3.3 million was spent on drug development (Moran et al., 2015). As a direct result, 
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many components of the antischistosomal drug discovery process are paltry or 
outdated.  
To begin with, industry-standard target-based drug screening approaches are not yet 
feasible. It is not yet possible to maintain neither a completely in vitro life cycle nor 
clonal cultures. Despite the sequencing of the 3 most important Schistosoma 
genomes and employment of in silico and C. elegans pre-screening approaches, 
drug targets continue to be poorly defined (Berriman et al., 2009; Keiser, 2015; 
Neves et al., 2015; Young et al., 2012; Zhou et al., 2009).  This is partly because, 
aside from sporadic RNAi knockout studies, well established gene manipulation 
methods are lacking to validate suspected targets (Guidi et al., 2015). It is possible 
that future applications of CRISPR/Cas systems might aid in this goal (Jurberg and 
Brindley, 2015). 
That being said, the majority of drugs approved by the FDA in the last decade have 
been identified by whole-organism and not target-based screens (Keiser, 2012). Thus 
the current gold standard for in vitro drug screening for schistosomiasis continues to 
be phenotypic microscopic evaluation of whole adult worms (Ramirez et al., 2007). 
This requires infection of mice or hamsters and their subsequent euthanization in 
order to extract the adult worms. This is not only animal unfriendly, it is also costly 
and time consuming (Keiser, 2010). As a direct result, the use of larval-stage worms 
as a pre-screening tool has been popularized. Larval stage worms can be easily 
obtained by mechanically transforming cercariae that are shed from infected snails, 
providing more worm material for drug screens with cheaper, faster and more ethical 
methods. However, microscopic assay evaluation is still a laborious and subjective 
bottleneck (Paveley and Bickle, 2013; Peak and Hoffmann, 2011).  
In the last decade, much has been done to attempt screening automation, albeit with 
mixed results. Fluorescent dyes, such as Alamar Blue or propidium iodide/fluorescein 
diacetate were shown to correlate with worm viability but still required a copious use 
of larvae. They can also only be used for endpoint assessments and fail to measure 
dose-response effects for some important drugs (Mansour and Bickle, 2010; Peak et 
al., 2010).  Microcalorimetry instrumentation could measure real-time heat flow as a 
proxy for adult worm viability, but was not sensitive enough for larval-stage worms, 
an issue also observed with the xCelligence impedance-based system (Manneck et 
al., 2011; Rinaldi et al., 2015). An image-based automated microscopic system was 
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described as a label-free method to evaluate helminth viability based on both 
morphology and motility (Paveley et al., 2012). Though usable for a yes/no screen, it 
has not yet been adopted for high-throughput dose-response assays and 
simultaneous real-time monitoring.  
In Chapter 2a and 2b, investigations of further fluorescence/luminescence-based 
drug assays and the use of a novel microcalorimetry device for assessing worm 
viability, respectively, are described.  
1.7 Drug rescuing and repurposing 
Another important bottleneck to drug discovery and development, for any disease, is 
the enormous cost and high risk of failure, in particular during the clinical phases of 
drug development. This clearly manifests itself at the end of the pipeline: in 2010,  the 
number of new chemical entities (NCE) was 50% lower than 5 years before (Paul et 
al., 2010). A 2013 assessment shows an even bleaker picture for NTDs, with no 
NCEs approved since the turn of the millennium (Pedrique et al., 2013). Drug 
repurposing, which is the application of on-the-market drugs or compounds in 
development for new indications, provides a means of circumventing these costs 
(Chong and Sullivan, 2007). In most cases, the pre-clinical and clinical safety testing 
has already been conducted; hence a repurposed drug candidate can often be 
accelerated to Phase 2 or 3 efficacy studies (Figure 4). Moreover, additional 
information, such as chemical, pharmacokinetic and analogue properties have 
already been determined and are usually available (Oprea et al., 2011). 
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Figure 4. Pathways to drug repurposing for marketed and shelved or withdrawn 
drugs. NCE= new chemical entity; ROA= route of administration (Adapted from 
Mucke, 2010) 
Anthelmintic drug discovery has already benefited much from this strategy, as many 
anti-nematodal drugs used for human infection have been repurposed from the 
veterinary field (Caffrey, 2012). Antischistosomal drug discovery has particularly 
profited from the antimalarial pipeline. Artemisinin and its derivatives, for example, 
have demonstrated potent activity against the juvenile stage of Schistosoma spp. in 
vivo (Keiser, 2012), and prophylactic and synergistic effects with praziquantel in 
clinical trials (Liu et al., 2011; Utzinger et al., 2000).  These promising revelations 
prompted investigations of “artemisinin-inspired” synthetic peroxide analogues as 
well as screens of an open-access library of antimalarial candidates, culminating  to 
the elucidation of several promising pre-clinical candidates (Ingram-Sieber et al., 
2014; Keiser et al., 2012; Xiao et al., 2011).  
In Chapter 3a, the anthelmintic drug repurposing landscape is reviewed in detail. 
Chapter 3b presents our repurposing efforts with a screening of an FDA-approved 
library of 1600 drugs.  
Just as on-the market drugs can be repurposed, failed lead candidates can be 
rescued. Famous examples include the shelved anti-cancer treatment, azido-
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thymidine, which was later rescued for HIV treatment and prevention or the toxic 
thalidomide, originally indicated as a sedative and later re-employed for multiple 
myeloma  (Reed, 2016; Singhal et al., 1999). Drug rescuing will likely continue to be 
an important source of new drug candidates, as demonstrated by the National 
Institutes of Health (NIH) National Center for Advancing Translational Sciences 
announcement of a significant drug repurposing initiative (Allison, 2012). In the case 
of schistosomiasis, rescuing old leads may prove to be a fruitful strategy, particularly 
because there are excellent antischistosomal candidates that were dropped once 
praziquantel’s dominance had clearly been established. In Chapter 4a and 4b, we 
describe the potent activity of Ro 13-3978, an antischistosomal candidate pursued in 
Roche and dropped at the pre-clinical phase (Keiser et al., 2010).  
Finally, it is also possible to leverage the known mechanism of action of an old or 
obsolete drug and remodel it to obtain more potent or less toxic analogues. For 
example, Filho and colleagues synthesized three oxamniquine derivatives which 
showed excellent activity against S. mansoni in vivo. Unfortunately, this was 
accompanied by higher toxicity and follow up derivatives were less potent (Filho et 
al., 2007, 2002). On the other hand, organometalic derivatization of compounds, 
especially ferrocene derivatives, has previously yielded promising antibacterial, 
anticancer and antimalarial candidates, with, for example, ferroquine already entering 
clinical trials (Hess et al., 2015). Moreover, chromium praziquantel derivatives have 
exhibited in vitro antischistosomal activity in the nanomolar range (Patra et al., 2013). 
In line with this successful strategy, we present potent in vitro and in vivo efficacy of 
novel organometallic derivatives of oxamniquine in Chapter 4c.  
 
1.8 Dynamics of schistosomiasis and praziquantel treatment in children  
As plans coalesce to place schistosomiasis on the road to elimination, it will be 
important to treat all those affected. It was previously thought that pre-school aged 
were not often exposed to sources of schistosome infections, yet epidemiological 
surveys from east and west sub-Saharan regions report prevalences of 14 – 86% in 
preschoolers (Ekpo et al., 2012; Stothard et al., 2011). Currently, praziquantel is used 
off-label to treat very young children diagnosed with schistosomiasis at the standard 
dose used for school-aged children and adults (40 mg/kg), but this is just a back-
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calculated extrapolation (Coulibaly et al., 2012). Proper dose-finding clinical trials for 
children younger than 4 years old have never been conducted (Keiser et al., 2011). 
Differences in drug digestion, absorption, metabolism and elimination in young 
children could mean that the praziquantel pharmacokinetic profile is quite different for 
this group, requiring different dosing regimens (Kearns et al., 2003). In recognition of 
this need, the Pediatric Praziquantel Consortium was thus formed with the aim of 
creating a single-dose pediatric formulation of praziquantel. Aside from removing the 
problematic bitter taste and the potentially inactive –S- enantiomer from the pill, an 
evidence base is needed to determine the effective dose. In Chapter 5a, we present 
a dose-finding study for praziquantel in pre-school age and school age children that 
attempts to provide this.  
 
1.10 Metabonomics to study schistosomiasis infection and treatment 
Though much is known about the organ and tissue level effects of schistosomiasis, 
increased insight into disease pathology could be extrapolated from molecular 
system-level analyses. Helminth “omics” is an ever-expanding field which promises to 
bring novel insight into host-parasite interactions and pharmacodynamics (Gaze et 
al., 2014; Nahum et al., 2012; Nóbrega de Sousa et al., 2013; Wang and Hu, 2014). 
Metabonomics is a relatively young field that is complimentary to other omics 
approaches. It is defined as the quantitative measurement of the metabolic 
responses of living systems to patho- physiological stimuli (Lindon et al., 2007; 
Nicholson et al., 2002). The development of powerful spectroscopic technologies 
such as 1H nuclear magnetic resonance (NMR), ultraperformance liquid 
chromatography (UPLC) or gas chromatography (GC) coupled with mass 
spectroscopy (MS) and capillary electrophoresis coupled with ultra violet 
spectroscopic detection (CE-UV), have allowed for identification of metabolites from 
multiple tissues and fluids at high resolution ((Nicholson et al., 1999)). However, such 
data is generally noisy, incomplete and contains copious inter-correlated variables 
per biological sample (Trygg and Lundstedt, 2007). Important developments in 
chemometrics, namely advances in pattern recognition, spectral alignment and pre-
processing, and supervised and unsupervised multivariate statistics have allowed for 
systematic analysis of inter-group differences and therefore an “omics” approach to 
analysis (Nicholson et al., 1999; Trygg, 2002; Veselkov et al., 2009).  
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Figure 5 (A) Metabonomics is complimentary to other “omics” approaches to 
study host responses to disease and other stimuli. (B) Workflow for NMR-
based metabonomic analysis. (Adapted from Goodacre, 2005; Veselkov et al., 
2009) 
Metabolic profiling of human biofluids has previously been employed to identify 
biomarkers of infectious as well as non-infectious diseases and to reveal drug-
response metabolic effects of treatment (Rozen et al., 2005). The former can be a 
source of novel diagnostics; the latter can provide insight into drug 
pharmacodynamics and pharmacokinetics, mechanisms responsible for individual 
variation in drug response and identify markers of treatment efficacy (Kaddurah-
Daouk et al., 2008; Lindon et al., 2004) 
Metabonomic studies of nematode and trematode rodent infection models have 
already brought interesting insights into the host-parasite interactions and system-
level dynamics of disease. Experiments with Echinostoma caproni, Fasciola hepatica, 
Necator americanus and S. japonicum rodent infection models show species-specific 
disturbances in metabolites related to energy metabolism (glycolysis, TCA cycle), 
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amino acid depletion, inflammation and microbial-mammalian co-metabolites,  in 
infected versus non-infected animals (Saric et al., 2009, 2010, Wang et al., 2009, 
2010; Wu et al., 2010). 1H NMR profiling analyses S. mansoni-mouse models 
exhibited metabolite alterations indicative of glycolysis stimulation, TCA cycle 
suppression and amino acid metabolism alterations indicative of liver damage. 
Moreover, alterations in microbial-mammalian co-metabolites, such as hippurate, 4-
cresol glucuronide and phenylacetylglycine, mirrored those observed in the above-
mentioned studies, while a significant reduction in urinary keto-acids was specific to 
the S. mansoni infection (Wang et al., 2004). A subsequent study using CE confirmed 
these findings, while detecting additional biomarkers of infection (García-Pérez et al., 
2008). A deeper investigation using magic angle spinning (MAS) NMR and multiple 
compartments showed the above-described metabolite alterations could be 
associated with inflammation and fibrosis in multiple organs, but also revealed 
metabolites associated with osmotic dysfunction in the kidneys, even while 
alterations were not detectable at the macroscopic level (Li et al., 2009).  
Despite these advances, metabonomic investigations of helminth infections in 
humans are rare. An initial attempt to profile 500 individuals with multiparasitism were 
not successful in revealing species-specific biomarkers, likely due to the large 
variability in age, genetic and behavioral differences, nutritional and socio-economic 
status and too much variation in type and intensity of helminth infections (Singer et 
al., 2007). Nonetheless, an investigation of onchocerciasis patients revealed 14 
infection-associated biomarkers (Denery et al., 2010) and later tyramine was 
identified as a diagnostic biomarker for Onchocerca volvulus infections (Globisch et 
al., 2013). Balog and colleagues looked at metabolic profiles of S. mansoni-infected 
adults and children and were able to characterize some discriminatory biomarkers of 
infection in adults (Balog et al., 2011). In Chapter 5b, we demonstrate how 
metabonomics can be used to study S. mansoni infection and its treatment in two 
important demographic groups: pre-school-aged and school-aged children.  
 
1.10 Aim and objectives 
The state of the antischistosomal drug development pipeline understates the urgency 
and impact of schistosomiasis. The lack of a vaccine and the wide-spread 
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dissemination of the only drug available to treat this important neglected tropical 
disease render schistosomiasis control vulnerable to rapid re-infection and potential 
drug resistance. New developments in drug assay technologies show potential to 
update the compound screening process to more objective and higher-throughput 
methods, but they still need improvement in accuracy, resolution and efficiency. 
However, even if identification of pre-clinical candidates is accelerated, de novo drug 
discovery is becoming increasingly costly and time-consuming. Therefore, drug 
repurposing and drug rescuing remain as important sources of potential novel 
antischistosomals. Meanwhile, there is still much to be understood about systemic 
impacts of this disease and its treatment with praziquantel in the demographic that is 
most affected- children.  
In this light, this PhD project had two main aims. The first aim was to bolster the drug 
discovery pipeline for schistosomiasis by investigating alternate in vitro screening 
systems and repurposing and rescuing old drugs into potential antischistosomals. 
The second aim was to expand our understanding of the pharmacodynamics of 
schistosomiasis and praziquantel treatment.  
This was pursued with the following specific objectives: 
1. To investigate an automated medium-throughput drug screening assay for 
Schistosoma mansoni. 
2. To review the drug repurposing landscape and identify potential antischistosomal 
compounds from a library of FDA approved drugs.  
3. To characterize the antischistosomal activity of the 3-arylhydantoin Ro 13-3978.  
4. To evaluate the in vitro and in vivo properties of novel organometalic oxamniquine 
derivatives.  
5. To elucidate the metabolic effects of schistosomiasis infection and its treatment 
with praziquantel in children.  
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6 Discussion  
 
Every few years, the global disease burden numbers are published, where schistosomiasis 
prevalence and disease burden numbers indicate that schistosomiasis remains a significant 
public health burden ((Murray et al., 2016; Murray et al., 2012; Vos et al., 2016). To that end, 
the World Health Assembly Resolution WHA 65.1  coupled with the London Declaration 
make for bold statements to place schistosomiasis on the path to control or elimination, by, 
amongst other things, increasing treatment coverage (Barry et al., 2013; Webster et al., 
2014). Yet ensuring proper coverage means ensuring all relevant populations are targeted 
and this includes pre-school aged children, for which special adaptations may be required 
(Stothard et al., 2013). Moreover, the increased distribution of praziquantel, while necessary, 
increases drug pressure and therefore places the antischistosomal therapeutic options in a 
nefarious situation. This is not an affordable risk and therefore, treatment alternatives and a 
modernization to the antischistosomal pipeline are required.  
The two main aims of the thesis were to boost the antischistosomal pipeline and to broaden 
our understanding of schistosomiasis infection and treatment needs of young children. Within 
the framework of the first aim, we sought to accelerate the drug screening process by 
investigating automated drug assay alternatives. We reviewed the drug repurposing 
landscape and leveraged it to screen a medium library of diverse FDA approved compounds. 
We sought to rescue an old antischistosomal lead, Ro 13-3978, and the now phased out 
oxamniquine, by profiling the activity and mode of action of the former and testing potent 
organometallic analogues of the latter. The second aim was carried out by undertaking a 
praziquantel dose-finding study to inform effective doses for a paediatric formulation. In the 
framework of this study, we elucidated the metabolic effects of infection and treatment in this 
group.  
Much of the results have been discussed in detail within the manuscripts. Here in this 
discussion, I would like to extract the lessons learned from these studies in order to outline 
prospects and challenges for the respective areas covered in this thesis, namely automated 
drug screening against S. mansoni, microfluidics and electrical impedance spectroscopy, 
drug repurposing and drug rescuing, treatment of pre-school aged children with praziquantel, 
and the relevance of metabonomic and integrated “omics” for schistosomiasis.  
 
6.1 Automated drug screens against S. mansoni 
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With publications of the S. mansoni, S. haematobium and S. japonicum  genomes and 
proteomes, combined with enzyme expression systems as well as advances in 
chemoinformatics, target-based screening is increasingly aiming to integrate into the 
antischistosomal drug discovery pipeline (Berriman et al., 2009; Neves et al., 2016; Sotillo et 
al., 2015; Verjovski-Almeida and DeMarco, 2008; Young et al., 2012; Zhou et al., 2009). 
Indeed, such approaches have helped to identify oxadiazole 2 oxides (though this candidate 
is no longer undergoing development) as well as a few other chemical entities such as 
thioredoxin glutathione reductase (TGR) and peroxiredoxin (Prx) inhibitors of S. mansoni 
(Sayed et al., 2008; Simeonov et al., 2008). Though this will continue to be an important 
developing field, an incessant issue is that in silico or enzyme-based target validation does 
not necessarily correlate to real biological systems, as demonstrated by our FDA screen and 
analyzed by Neves et al. (Neves et al., 2016; Panic et al., 2015b). Validation with a whole 
organism screen is always required and therefore in silico approaches are rather 
complementary and informative instead of a replacement (Neves et al., 2016). 
Indeed, whole organism screening remains the most important source of new chemical leads 
for helminths and the drug discovery field in general (Caffrey, 2012; Lang et al., 2006). Yet 
the drawbacks of the current standard of compound evaluation, manual microscopic 
evaluation, are undeniably an obstacle to processing large compound libraries and, in 
addition, can be subjective (Peak and Hoffmann, 2011; Ramirez et al., 2007).   
In our pursuit to establish an automated and higher throughput drug sensitivity assay for S. 
mansoni NTS (larval-stage worms), we explored a plethora of options. The easiest and most 
obvious was to simply add a fluorescent or luminescent dye to the existing assay where the 
fluorescence or luminescence signals are a proxy for worm viability or cytotoxicity and can be 
read by a simple plate reader. Indeed, many such assays have been validated before, be it 
for cell lines or protozoans (Page et al., 1993; Smilkstein et al., 2004; Sykes et al., 2012). 
The ways in which such dyes function are thoroughly described in Chapter 2a, hence I will 
not review them again.  
Of the 11 markers tested, we were successful in identifying only one, CellTiter-Glo®, that 
appeared to correspond well to worm viability. Moreover, its use in a small screen allowed for 
identification of single drug concentration “hits” (with 100% correspondence to hits identified 
by visual assessment) as well as extrapolation of IC50 values for some drugs. Incidentally, 
Lalli and colleagues also published on the CellTiter-Glo® assay with similar findings, (Lalli et 
al., 2015). Though this presents a development towards automation, there are clear 
limitations with this and marker-based assays in general. First, the use of CellTiter-Glo® 
method incorrectly classifies praziquantel as completely inactive at concentrations that are 
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known to severely damage larval-stage worms (confirmed by both publications). As we 
discussed in Chapter 2a, this phenomenon is not unique to this assay, but is observed also 
in other marker-based assays and in isothermal calorimetry (Manneck et al., 2011; Mansour 
and Bickle, 2010; Peak et al., 2010). The reasons for this are unknown, however 
praziquantel is known to disrupt Ca2+ homeostasis, which could potentially disrupt 
mitochondrial ATP production (Chan et al., 2013; Tarasov et al., 2012). As anthelmintics 
often operate by disrupting ion homeostasis, which could affect ATP homeostasis, these 
phenotypes could be missed in such screens (Greenberg, 2014; Khanna et al., 2014).  
This leads to the second point- though Lalli et al. used this method for a larger 1712 
compound screen, the accuracy of the assay has not been properly validated for a large-
scale library (Lalli et al., 2015). A z-score for each assay was calculated, but this is only a 
measure of assay quality based on signal variation (Zhang et al., 1999). Accuracy validation 
would require a visual microscopic cross-check for a larger compound library, which we 
performed in our publication on a very small sub-set of compounds. However, we decided 
not to validate further because of the marker’s above-mentioned and two additional 
limitations, namely its cost and single-point measurement. In other words, consumable costs 
for CellTiter-Glo® are too high -and for us, not worth investing into making a cheap “in 
house” version- to justify replacing visual assessment.  Moreover, dye-based assays in 
general are suitable for only one end-point screen; if additional time-points are desired, 
additional assay set ups are required (Peak and Hoffmann, 2011). I will elaborate on the 
importance of this latter point later on. In brief, in theory it is possible to use this method for 
large-scale Yes/No screens, if one decides the possible false negatives and cost of 
consumables are acceptable, however it would be prudent to conduct additional validation 
steps.  
In recognizing these limitations, we aimed to investigate a label-free method where additional 
time-points could be measured. In that light, investigations with the novel calScreener™ 
isothermal calorimeter appeared promising. Initial investigations by Manneck et al. showed 
good correlation to adult worm viability but required 400 to 1000 NTS per replicate to observe 
any signal (Manneck et al., 2011). The calScreener™ should have greater sensitivity due to 
its smaller ampules (300 µl volume vs 3 ml for the TAM 48) and their increased heat capacity 
(Braissant et al., 2015). Indeed, as we demonstrated, it was more sensitive to picking up 
adult worm activity for a number of helminths including S. mansoni. However, NTS heat flow 
could still not be sufficiently detected and the small ampule volume proved to be too small for 
adult S. mansoni to survive. From this and previous studies, I would conclude that 
microcalorimetry is an excellent tool to more specifically characterize compound activity on 
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adult-stage helminths, but it would take major developments for it to be sensitive enough for 
larval stage screens (Flores et al., 2015; Manneck et al., 2011; Tritten et al., 2012).  
Developments in high-content microscopy drove the development of a label-free high-
throughput image-based system screening assay for S. mansoni larvae (Paveley et al., 2012; 
Starkuviene and Pepperkok, 2007).  In their initial paper, they described a method in which 
both motility and morphology of NTS could be scored using image overlay software and a 
library of NTS drug-treated phenotypes. Recently, they published their screen of 300 000 
compounds employing this method, of which 18774 NTS hits were presented (Mansour et 
al., 2016). Although this definitely presents as the largest screening campaign conducted on 
S. mansoni NTS thus far, improvements to this system are both possible and necessary. 
First, the original published protocol shows praziquantel as having a moderate effect on NTS 
morphology and an overall combined morphology/motility effect score in the range of 
oxamniquine. Yet as mentioned, praziquantel has a rather severe morphological effect on 
larval schistosomes, whereas oxamniquine only has a minor one, and in manual screens the 
IC50 values for these two compounds are at least an order of magnitude apart (Meister et al., 
2014; Panic et al., 2015a). Since both are classified as hits under the protocol, likely many 
false positives are generated as also indicated in their initial publication. Second, again, both 
onset of action and IC50 values are not yet determinable using this approach. It is arguable 
that this is simply a pre-screening method and that more refined methods can be applied at 
the adult worm in vitro screening stage. Yet the increasing availability of compounds for 
repurposing would allow us to compare these two parameters -onset of action and in vitro 
IC50 values- with available pharmacokinetic parameters which, when combined, could be 
more indicative of good in vivo activity than simply yes or no screens. In the section that 
follows, we present a platform that could potentially offset the drawbacks and make the case 
for how this could be useful in the antischistosomal screening cascade.  
 
6.2 Microfluidics and electrical impedance spectroscopy for in vitro drug screening 
against S. mansoni NTS 
The field of microfluidics coupled with electrical impedance spectroscopy (EIS) is rapidly 
expanding into the drug discovery realm (Kang et al., 2008). Microfluidics allows for the 
handling of biological organisms at single-cell resolution and a tight control of its 
microenvironment. Consequently, microfluidic devices have been successfully applied to 
study organisms such as invertebrate and vertebrate embryos, tissue samples or cultured 
tissue spheroids and even C. elegans at various growth stages (Haandbæk et al., 2014). 
Meanwhile EIS allows for the study of electrical properties of such organisms, which can 
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reveal information about changes in cell/tissue structure, membrane integrity and even 
organelles (Bürgel et al., 2015).  
In 2014, in order to search for automated compound screening alternatives, we started a 
collaboration with the Bio Engineering Laboratory (BEL) group at the ETH Zürich on a 
microfluidic platform for evaluating S. mansoni NTS viability using electrical impedance 
spectroscopy (EIS), at single larvae resolution. A simple EIS microfluidics chip was 
fabricated to test if NTS viability could be measured using such a device (Fig 1A). The 
general principle theory is as follows: a microfluidic channel filled with medium and a single 
NTS is interfaced with two electrodes. When a current is applied an electric field is generated 
between the electrodes. A passing object (in this case the NTS) creates resistance to the 
current which is proportional to membrane permeability (i.e. membrane damage) as well as 
object size, amongst other things. The impedance can be measured and correlated to 
visually inspected worm viability. Initial results indicate differential impedance signals 
between live and dead NTS across a range of frequencies. (Fig 1B and C). 
 
Figure 1 A) Test chip with a single microchannel and platinum electrodes, wherein single 
NTS can be cultured and measured for B) Impedance of a single NTS (replicates) and C) 
phase lag over increasing frequencies.  
Subsequent tests measured if not only morphological properties but also motility could be 
measured using this system. This is based on the fact that impedance is altered according to 
changes in both the area and length of the object, which can correspond to NTS 
contractions. Our tests show sizable fluctuations in impedance with motile NTS and no 
significant fluctuations from non-motile NTS (Fig 2A). These fluctuations can be correlated to 
gradients in motility resulting from exposure to serially diluted drug concentration from which 
an IC50 value can be extracted (Fig 2 B).  Because it is possible to culture the NTS within the 
chip, all of these parameters can be measured at single time-points or continuously.  
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Figure 2 Impedance and phase fluctuations are observable for moving NTS. (A) A 
recording was taken of a viable NTS pegged between two electrodes; here a snapshot at 
15.07 s and 26.13s. B) NTS treated with a dilution series of an in vitro active drug, 
lomerazine, show gradually decreased capabilities in motility, which are measurable 
using EIS. These were converted to an IC50 value (0.56 µM) that was near identical to the 
value determined by manual microscopy (0.54 µM). 
The ability to characterize NTS drug responses at single or over several time points and at 
single or multiple drug concentrations (using only a few larvae) would present as another and 
precise automated screening method. However, it also provides richer quality data, which 
allows us to take this device a step further towards more informative in vitro lead selection.  
The ability to screen a high content of compounds on NTS (as displayed by Paveley et al.) 
brings into question how to prioritize hits. Often it has been the case that a compound 
exhibits excellent in vitro activity, with a low IC50 and a rapid onset of action on all worm 
stages, yet is inactive or poorly active in vivo (Cowan and Keiser, 2015; Guidi et al., 2016; 
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Ingram-Sieber et al., 2014). Several assays can be employed after activity characterization to 
help estimate, for example, cytotoxicity (such as the L6 rat skeletal assay), the logP of the 
compound (such as the PAMPA assay), or compound stability in the face of liver metabolism 
(such as the microsomal stability assay) (Cowan et al., 2015; Gülden, 1993; Obach, 2001). 
These are, however, laborious additional steps with extra costs.  
Conversely, there is no way to identify a prodrug (a drug where not the parent compound but 
its metabolites are active) without testing in vivo first. This is both ethically and logistically not 
feasible with a compound library. Though we could in theory accept this as an affordable 
loss, many drugs are actually prodrugs and neither of the very active in vivo compounds 
discussed in Chapter 4 would have been captured in a typical screening cascade (Filho et 
al., 2007, 2007; Valentim et al., 2013). 
Beyond evaluating drug effects on NTS, we envisioned a means of stream-lining the above 
described processes by leveraging recent “body on a chip” (BoC) developments (Bhatia and 
Ingber, 2014; Huh et al., 2010). Human spherical microtissues can be grown in a hanging 
drop format and their functionality also assessed in a microfluidic EIS chip (Frey et al., 2014). 
Such tissues have been used, among other things, to assess cardiotoxicity and 
hepatotoxicity, which might be more accurate and informative than using single enzymes or 
cell lines (Kunz-Schughart et al., 2004).    
In our conceptualized “infected body on a chip” (iBoC), NTS and spheroid cultures could be 
co-cultured to measure drug efficacy and toxicity simultaneously (Fig 3A). In addition, 
incubating the drugs with both the liver tissue and the NTS could reveal if in vivo activity is 
expected to be minimal due to drug metabolism, or conversely, if an in vitro inactive drug 
becomes active upon liver metabolism. Many different chip designs can be fabricated for the 
different drug assays described and integrated on a single platform (Fig 3B).  
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Figure 3 (A) Integrated NTS and spherical tissue in a single channel can test cytotoxicity as 
well as effects of liver metabolism on drug activity. (B) Different chip designs can be 
integrated on a single platform for simultaneous and continuous read-outs.  
The project requires developments in handling, optimal co-culturing and evaluation 
parameters and chip design, as well as read-out software for mutli-channel impedance read-
outs. These developments are underway, supported by the recent awarding of an SNF 
Interdisciplinary Grant in collaboration with the group from BEL.  
 
6.3 Drug repurposing challenges and opportunities 
There is no doubt that drug repurposing has been an extremely important source of 
anthelmintics and pre-clinical antischistosomal candidates, as reviewed in Chapter 3a. Since 
its publication, a number of marketed drugs have been tested on Schistosoma spp., some 
with more success, such as the chlorambucil anticancer drug showing a 75% WBR in 
juveniles (Eissa et al., 2017), and some with less success, such as the poor in vivo activity 
observed for histone/lysine deacetylase inhibitors (Chua et al., 2017).  
The repurposing approach is likely to continue as an important source of new leads, 
especially with increasing avenues for compound sharing, such as the aforementioned NIH 
initiative for drug repurposing or the Re-search Wisdom Research program (Allarakhia, 
2013). Moreover, screens of already marketed drugs bring new information about active 
pharmacophores which can be shared via open source databases such as DrugBank or 
Therapeutic Target Database (Knox et al., 2011; Ma’ayan et al., 2007) which can further be 
explored using cheminformatics approaches and SAR studies (Neves et al., 2016). 
All this presents exciting opportunities for antischistosomal drug discovery, yet this does not 
guarantee a cornucopia. There are some pitfalls to this approach, which are important to 
examine.  First, as we saw with our FDA library screen, many compounds are a priori not 
suitable for oral treatment, as they are either toxic, or poorly absorbed. They may also only 
be active at a dose that is much different from its original indication. As described in Figure 4 
of the introduction, such compounds would then need to be treated as an NCE, which 
defeats some of the advantages of repurposing (Mucke, 2010). This would then rather be an 
informational screen about potentially active pharmacophores which is nonetheless 
informative, even if not truly a repurposing effort.  
There may also be a drawback to repurposing drugs with an existing target in humans. In our 
FDA screen, a very interesting group initially was the angiotensins/ antihypertensives. In 
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vitro, they displayed both low inhibitory concentrations as well as a rapid onset of action. The 
potent in vitro activity was also intriguing due to the indicated target of these compounds, 
calcium ion or voltage-gated ion channels, which is purportedly also the target of 
praziquantel, as well as other anthelmintics. It might have indicated an interesting group of 
compounds to further explore. In addition, their published pharmacokinetic profiles indicated 
good absorption, which is complementary to their intended target, the blood-dwelling 
schistosomes.  However, in vivo, they displayed mild activity at best. A similar finding was 
presented by Guidi et al. who studied the in vitro and in vivo efficacy of perhexiline, a drug 
that was also potent in our FDA screen, but that we decided not to pursue do to its known 
hepatotoxicity (Guidi et al., 2016). On the one hand, it’s possible that clearance is too quick 
to act on the worms, though we crosschecked the onset of action with the ADME profile. 
Moreover, praziquantel itself is quickly cleared, but because it is fast acting, the AUC 
achieved is sufficient to clear the worms (Meister et al., 2014). Many of these drugs are 
highly protein binding, yet the relationship between protein binding and in vivo efficacy is not 
straightforward (Smith et al., 2010). Hence, since these compounds have a direct target in 
the host, and in addition, are distributed throughout the circulatory system, they might indeed 
be binding stronger to their “indicated” target than to the schistosomes. Here, target docking 
studies would be of interest to assess differential binding affinities.  
Finally, even if the repurposed drugs display excellent pre-clinical profiles, caution should be 
exercised when thinking about their field applications. This was emphasized when the 
intriguing pre-clinical and clinical profiles of the antimalarials mefloquine and the artemisinins 
against schistosomiasis were described (Keiser et al., 2010, 2014). It was warned that due to 
their importance in antimalarial control, these should not be broadly applied for 
schistosomiasis preventative chemotherapy (Keiser and Utzinger, 2012).  
Nonetheless, many of these investigations can be a short-cut to uncovering new 
pharmacophores that are active against Schistosoma spp. Indeed, precisely the mechanism 
of action and structure-activity relationship studies of the artemisinins inspired a new 
generation of synthetic peroxides with analogues that are active against Schistosoma spp., 
(Boissier et al., 2009; Keiser et al., 2012). These can further be fed into open source drug 
banks and chemoinformatic databases to better inform both Schistosoma drug targets as 
well as promising drug scaffolds for further re-design (Neves et al., 2016), the latter of which 
lead to successful in vivo active organometallic oxamniquine derivatives discussed below.  
 
6.4 Drug rescuing and redesign 
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In our investigation of the dropped antischistosomal candidate, Ro 13-3978, we 
characterized the potent activity of this compound against all worm life stages, which was 
more efficacious than praziquantel in vivo.  Despite its broad stage activity, Ro 13-3978 was 
found to be very species-specific, with no activity against the related trematodes, 
Echinostoma caproni and Fasciola hepatica. Its rather weak activity in vitro was contradictory 
to its potency in vivo, and the lack of significant structural damage in vitro was confirmed with 
our SEM studies comparing worms exposed to high concentration of the drug in vitro and ex-
vivo worms treated with 100 mg/kg. The SEM studies coupled with hepatic shift experiments 
were also revealing of the onset of action; at 24 h some disruptions to the tegument are 
visible but by 48 h, the tegument is completely damaged. Dispelling the notion that it is a 
prodrug (Ro 13-3978 was stable when incubated with liver microsomes), this time frame, 
along with some visible but vague and unidentifiable cell attachments to tegument (not 
shown) prompted the theory that activity could somehow be immune-mediated, as was 
demonstrable for praziquantel and oxamniquine (Doenhoff, 1989).  
In considering the size of the adult worm, it was decided that a good first approach to 
investigating this theory was with immunohistochemical staining of mesenteric vein and liver 
sections, from S. mansoni-infected mice, containing the worm at 24 and 48 h post-treatment 
(before and after hepatic shift and around the onset of action). In contrast to other 
techniques, such as fluorescence-activated cell sorting flow cytometry (FACS), this allowed 
us to illustrate the recruitment of leukocytes to the locus of infection, rather than just 
adjustments in circulating cells (Dunphy, 2004). We observed a significant increase of 
macrophages and B cells to the infection site in the veins at 24 h, and recruitment of T cells 
and some neutrophils at 48 h post-treatment. In comparing this to our sections of 
praziquantel, oxamniquine and mefloquine-treated mice, we noted that similar responses 
occur after treatment with these drugs as well, however to a different magnitude. Mefloquine 
treatment, for example, results in some macrophage recruitment, while oxamniquine and 
praziquantel induce recruitment of far more macrophages within a similar time-frame. To 
place it in context, Ro 13-3978 is somewhere in between. As we discussed in Chapter 4b, 
when these results are compared to published onset of action and SEM studies, immune-cell 
recruitment is not necessarily correlated to rapid tegument degradation, which elicits 
questions of drug-immune cell interactions.  
To understand these findings further, two lines of investigation are planned. The first is to 
culture Ro 13-3978 and comparator drugs with phagocytes and lymphocytes to observe if 
these cells are activated by the drug. This is being undertaken by Dr. Paul Davies from the 
University of Nebraska, Omaha as well as by in house studies. Furthermore, we would like to 
classify the sub-populations of the cells we labeled, by for example, employing markers 
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specifics for dendritic cells vs. macrophages vs. Kupfer cells and to identify if and how the 
recruited cells are activated. In doing so, we would like to illustrate further the relationship 
between chemotherapy, the immune system and clearance of S. mansoni worms.  
As for identifying the target of Ro 13-3978, this may prove to be a bit more challenging. For 
example, although Ro 13-3978 is a close structural analogue to nilutamide, an androgen 
receptor antagonist, it has been shown that its antischistosomal activity is not related to 
androgen receptor binding (Wang et al., 2014). Initially, we had hoped to try and identify the 
target using affinity chromatography with S. mansoni lysed extracts, as previously described 
(Manneck et al., 2012), however conversations with our chemist, Dr. Jonathan Vennerstrom, 
revealed that it was difficult to synthesize a linker to Ro 13-3978 that was stable in the pH 
requirements for affinity chromatography. Moreover, the recently explored click chemistry 
approach of tracking drug alkylation of proteins was not possible, as an alkyne derivative is 
not synthesizable for this drug (Ismail et al., 2016). Further possible approaches may include 
photo-affinity labelling (PAL) or fluorescent tagging, though they might encounter similar 
chemical synthetic challenges (Schenone et al., 2013; Smith and Collins, 2015). Perhaps 
with further refinement of chemoinformatic techniques described above, combined with novel 
gene knock-out technologies, target identification may be more easily attainable (Jurberg and 
Brindley, 2015; Neves et al., 2016). 
Indeed, target identification isn’t just a fun game for basic research scientists. The synthesis 
of the organometallic oxamniquine derivatives we tested were guided in part by the well 
described interaction of oxamniquine to its sulfotransferase target. This provides an example 
of how such information can be translated to the possible rescue of an otherwise obsolete 
drug (Pica-Mattoccia et al., 2006). The ferrocenyl, ruthenocenyl and benzyl oxamniquine 
derivatives displayed in vivo activity against S. mansoni on par with oxamniquine, but 
importantly, far more potent in vitro activity. This is interesting for two reasons. First, it may 
indicate a different mode of binding to the target than oxamniquine, which could be more 
flexible or independent of co-factors such as PAPS (required for oxamniquine binding) 
(Valentim et al., 2013). Or it could indicate a different target altogether. Moreover, our 
histological examinations and previous evidence indicate that oxamniquine also relies on 
immune assistance and requires about 3 days to start clearing worms from the veins in vivo 
(Botros et al., 1989; Fallon et al., 1992, 1996). The rapid onset of action of organometallic 
derivatives may be reflective of their in vivo kinetics, though further studies would be required 
to elucidate that. Either way, both possibilities may mean these compounds could also be 
active in other Schistosoma spp. important to humans, namely, S. haematobium and S. 
japonicum. Testing with these drugs against S. haematobium is planned.  
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6.5 Dynamics of praziquantel treatment in school-age and pre-school age children  
Since the London Declaration of 2012 has set a global aim to place schistosomiasis on the 
path towards control by 2020, there was an acknowledgment that an increase in treatment 
coverage is necessary (Barry et al., 2013). Contemporarily, evidence had accumulated that 
the target population for preventative chemotherapy programs should expand to pre-school 
aged children, as many were found to harbor infections of varying intensity (Stothard et al., 
2013). However, the doses provided to very young children were simply back-calculated from 
doses intended for adults, which is a compromise at best. Many of these doses would be in 
the form of half a tablet or tablet which are too crudely adjusted to the children’s small 
weight. Moreover, due to their size, the tablets need to be crushed and swallowed with liquid, 
producing a very bitter taste (Meyer et al., 2009). The latter point might appear cosmetic and 
trivial, but it bears significant consequences for treatment adherence and appropriate dosing, 
as it is difficult for many young children to keep the medication down (Coulibaly et al., 2012). 
Finally, the metabolisms and immune responses of very young children vary from those of 
adults, which could greatly influence the pharmacokinetics and efficacy of praziquantel.   
In response to this important medical need, the Pediatric Praziquantel Consortium was 
formed to fabricate pediatric formulations of praziquantel (Pediatric Praziquantel Consortium: 
http://www.pediatricpraziquantelconsortium.org). However, since it will take another several 
years untill the new tablet formulation is available, it was our goal is to generate an evidence 
base for the effective dose and pharmacokinetic profile of praziquantel in very young 
children, which was the aim of our dose-finding study (Coulibaly et al., under review). To 
make a robust comparison, school-age children and placebo groups were included. Our 
study presented several important findings which have been discussed in the paper, though I 
would like to reiterate and elaborate on a few points. First, the study added to the evidence 
that pre-school aged children are affected by schistosomiasis. Though many bore light 
infections, 20% bore moderate to heavy infections. Considering the pathology of 
schistosomiasis, it is plausible that from a very young age, childhood development is affected 
by this chronic disease, as is likely the case for other helminthiases (Kvalsvig and Albonico, 
2013). It is, however, difficult to ascertain the directionality of this altered development and 
difficult to design robust longitudinal studies (Müller et al., 2011).  There is evidence that 
helminth infection can promote inflammatory homeostasis by triggering immunoregulatory 
responses (Mishra et al., 2014). Nonetheless, considering the widespread and cumulative 
pathology of schistosomiasis, it is likely better to remove the infection as early as possible 
(Gray et al., 2011). 
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We presented evidence that the efficacy of praziquantel in pre-school aged children infected 
with S. mansoni is somewhat diminished. This could be in part due to the lower infection 
intensity observed for pre-schoolers and therefore lower diagnostic precision for this group. 
However, considering that both Kato-Katz and POC-CCA tests (whether “trace” was 
interpreted as positive or negative for POC-CCA) showed a similar trend, there might be 
other reasons. One point, for example, is the oft cited immunomodulatory effects of 
praziquantel. As we reviewed in our histological examination of drug-treated mice (Chapter 
4b), clearance of worms after treatment with praziquantel is greatly aided by host T-cell, B-
cell and antibody responses (Brindley and Sher, 1987; Doenhoff, 1989).  Yet immune 
responses in young children are very different from older children, with regards to Th1 versus 
Th2 response orientation, antibody production as well as cytokine response (Jaspan et al., 
2006; Prescott, 2003) and this could very well influence treatment efficacy. This could mean 
that, as we suggest, the paediatric formulation may require higher doses of praziquantel, or 
an adjuvant, though the latter complicates clinical trials and administration.  
With the aim of elucidating molecular processes behind schistosomiasis and treatment with 
praziquantel, we undertook a metabonomic investigation of pre-treatment, 24h post-
treatment and follow up urine samples from this clinical trial. Our findings revealed metabolic 
differences in several sub-groups. First, we characterized our population before treatment 
intervention where pre-schoolers and school-aged children were found to have fairly 
differential metabolic profiles with respect to muscle mass, energy and gut microbial 
metabolism, results which were largely in line with previous metabonomic characterizations 
in children, (Gu et al., 2009). These could have important implications for the differential 
treatment outcomes between school-aged and pre-school aged children, described above.  
Infection status could also be differentiated with a metabolic fingerprint, however only for 
heavy infections and only before intervention. Metabolites were largely associated with 
metabolic pathways associated with the liver and, intestinal permeability and gut microbiota. 
The instability of the metabolites at 3 week follow up could rather reflect the nature of the 
disease- though the infectious agent is cleared, the pathology persists and therefore those 
that are not infected might still share similar metabolic signatures as those that are infected. 
This, unfortunately, rather indicates that a metabolic marker for infection was not retrievable. 
However, it may be useful for studying progression or regression of general disease 
pathology, though more longitudinal studies would be warranted.  
Finally, several metabolic signatures were correlated to uptake of praziquantel. Considering 
the immediate antischistosomal effects of praziquantel (only 30 min for hepatic shift) and its 
supposed immunomodulatory action, this is perhaps not surprising. Our models show the 
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effect is transitory as, at follow up, no significant differences even between 60 mg/kg and 
placebo can be seen. Interestingly, metabolic responses of pre-schoolers vs school-aged 
children to praziquantel treatment were alike with the exception of a few gut microbial 
metabolites. This suggests a possible role of the gut microbiota in praziquantel treatment 
success, which was partly reflected by findings from Schneeberger et al. (2018), a study 
conducted using stool samples from the same trial.  
At the moment, these metabolic signatures provide first snap shots into metabolic differences 
between school age and pre-school age children and the dynamics of schistosomiasis 
infection and its treatment. In a next step, we would like to integrate the findings from our 
metabonomic investigations with gut microbiome investigations from stool samples 
(Schneeberger et al., 2018) and pharmacokinetic profiling from dried blood spots (Kovac et 
al., 2018) from the same clinical trial, to provide a system-level “omics” analysis of 
parameters of interest such as the correlations between microbiome and drug uptake and 
metabolic and microbial predictors of treatment efficacy or failure. This would require a 
deeper-level analysis, employing further orthogonal multivariate statistics such as Two-Way 
Orthogonal Partial Least Squares (O2PLS) or penalized regression methods (LASSO and 
ENET) (Bouhaddani et al., 2016; Pineda et al., 2015). Pharmacometabonomics, the 
integration of pharmacokinetics and metabonomics, has been successfully employed for 
personalized medicine purposes such as detecting metabolic correlates to drug uptake and 
adverse events, which can be more informative than pharmacogenomics, as it takes into 
account environmental factors (Clayton et al., 2009a; Huang et al., 2015). Moreover, there is 
mounting evidence that host-microbial interactions are integral to drug metabolism and 
response, which can be well characterized by integrating microbiome and metabolome 
profiles (Clayton et al., 2009b; Wilson, 2009). Apart from gaining interesting insights into the 
dynamics of microbiota, schistosomiasis and praziquantel treatment, it could also inform 
differential treatment needs between very young and older children with respect to treatment 
dose, nutritional requirements and innate inter-individual variation. As treatment with 
praziquantel is often blemished by a few cases of treatment failure, such an investigation 
would help in illuminating the factors involved and teasing apart host and environmental 
factors from potential resistance.  
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